Aurora BioPharma is a leading biotechnology company based in Cambridge, MA, specializing in the development of innovative cancer immunotherapy treatments. Their expertise lies in Chimeric Antigen Receptor (CAR) T therapy, Cancer Vaccines, and combinations with Checkpoint Inhibitors, with promising results in pre-clinical and human clinical trials.
The company has successfully completed Phase 1 clinical trials for their CAR T agent, AU105, in Glioblastoma and Sarcoma patients, demonstrating safety, tumor killing efficacy, and promising signals of improved overall survival. Aurora BioPharma is now planning Phase II trials for AU105 in Early Diagnosed Glioblastoma and Osteosarcoma, as well as combination trials with their p53 DC cancer vaccine in lung cancer.
Generated from the website